Quanterix Corporation (QTRX)
| Market Cap | 156.78M |
| Revenue (ttm) | 138.90M |
| Net Income (ttm) | -107.15M |
| Shares Out | 46.94M |
| EPS (ttm) | -2.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 991,777 |
| Open | 3.190 |
| Previous Close | 3.210 |
| Day's Range | 3.160 - 3.370 |
| 52-Week Range | 3.040 - 8.770 |
| Beta | 1.32 |
| Analysts | Hold |
| Price Target | 6.00 (+79.64%) |
| Earnings Date | May 6, 2026 |
About QTRX
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, s... [Read more]
Financial Performance
In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $6.0, which is an increase of 79.64% from the latest price.
News
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregiona...
Quanterix Debuts Content Innovation Engine at AACR 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeti...
Quanterix Corporation Announces Date of 2026 Annual Meeting
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Co...
Quanterix Transcript: Leerink Global Healthcare Conference 2026
Leadership is prioritizing diagnostics and sustainable growth, leveraging the Akoya acquisition for diversification. Financials are strong, with synergy targets met and a conservative 2026 outlook. Diagnostics and Simoa ONE products are positioned as market differentiators, while operational focus shifts from cost-cutting to growth.
Quanterix Transcript: TD Cowen 46th Annual Health Care Conference
Management outlined a strategy focused on diagnostics growth, especially in Alzheimer's, leveraging a strong recurring revenue base and successful Akoya integration. Financial performance exceeded expectations, with robust consumables demand and margin improvements. A comprehensive diagnostics plan and further international expansion are key priorities for future growth.
Quanterix Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose 25% year-over-year to $43.9 million, with strong academic demand and expanded diagnostics partnerships. 2026 guidance targets $169–$174 million revenue, cash flow breakeven in H2, and continued investment in Alzheimer's diagnostics and assay innovation.
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on...
Quanterix to Participate in Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has...
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced public...
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced public...
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the pu...
Quanterix Earnings Call Transcript: Q3 2025
Q3 revenue grew 12% year-over-year to $40.2 million, driven by strong integration progress and early cross-selling between Simoa and Spatial platforms. Despite academic and pharma market headwinds, cost synergies and R&D investments position the company for growth and profitability in 2026.
Quanterix Releases Financial Results for the Third Quarter of 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ...
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Departmen...
Quanterix Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Guidance for 2025 anticipates a core business decline, but consumables and diagnostics show resilience. Integration with Akoya is progressing, with $85M in synergies targeted by 2026 and a focus on assay innovation, menu expansion, and new diagnostic launches.
Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadershi...
Quanterix Earnings Call Transcript: Q2 2025
Q2 revenue fell 29% year-over-year to $24.5 million amid academic and pharma funding headwinds, but cost actions and the Akoya acquisition position the company for long-term growth. Guidance for 2025 is $130–$135 million in revenue, with $85 million in synergy savings targeted.